Tacrine and its 7-methoxy derivate; time-change concentration in plasma and brain tissue and basic toxicological profile in rats

References

• Adem, A., 1992. Putative mechanisms of action of tacrine in Alzheimers disease. Acta Neurologica Scandinavica, 85(S139), 69–74.
   Web of Science ®Google Scholar
• Albin, M.S., et al., 1975. Tetrahydroaminoacridine antagonism to narcotic addiction. Experimental Neurology, 46(3), 644–648.
   PubMed Web of Science ®Google Scholar
• Ames, D.J., et al., 1988. Hepatotoxicity of tetrahydroaminoacridine. Lancet (London, England), 1(8590), 887.
   PubMed Web of Science ®Google Scholar
• Bajda, M., et al., 2015. Synthesis, biological evaluation and molecular modeling of new tetrahydroacridine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Bioorganic and Medicinal Chemistry, 23(17), 5610–5618.
   PubMed Web of Science ®Google Scholar
• Bajgar, J., Bisso, G.M., and Michalek, H., 1995. Differential inhibition of rat brain Acetylcholinesterase molecular forms by 7-methoxytacrine in vitro. Toxicology Letters, 80(1–3), 109–114.
   PubMed Web of Science ®Google Scholar
• Becker, R., and Giacobini, E., 1997. Alzheimer disease: from molecular biology to therapy. Basel: Birkhauser.
   Google Scholar
• Bi, X., 2010. Alzheimer disease: update on basic mechanism. Journal of American Osteopathic Association, 110(9 Supplement 8), 3–9.
   Google Scholar
• Castellani, R.J., Rolston, R.K., and Smith, M.A., 2010. Alzheimer disease. Disease-a-Month: Dm. 56(9), 484–546.
   PubMed Web of Science ®Google Scholar
• Cheffer, A., and Ulrich, H., 2011. Inhibition mechanism of rat α3β4 nicotinic acetylcholine receptor by the Alzheimer therapeutic tacrine. Biochemistry, 50(11), 1763–1770.
   PubMed Web of Science ®Google Scholar
• Cook, M.R., et al., 2002. Physiological and performance effects of pyridostigmine bromide in healthy volunteers: a dose-response study. Psychopharmacology, 162(2), 186–192.
   PubMed Web of Science ®Google Scholar
• Crismon, M.L., 1994. Tacrine: first drug approved for Alzheimer's disease. Annals of Pharmacotherapy, 28, 774–751.
   Web of Science ®Google Scholar
• Davis, K.L., and Powchick, P., 1995. Tacrine. Lancet (London, England), 345(8950), 625–630.
   PubMed Web of Science ®Google Scholar
• Davis, K.L., et al., 1992. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. New England Journal of Medicine, 327(18), 1253–1259.
   PubMed Web of Science ®Google Scholar
• Dejmek, L., 1990. 7-MEOTA. Drugs of the Future, 15(2), 126–129.
   Google Scholar
• Drtinova, L., Dobes, P., and Pohanka, M., 2014. Low molecular weight precursor applicable for Alzheimer disease drugs synthesis (AChE and BChE inhibition, BACE inhibition, antioxidant properties and in silico modulation). Journal of Applied Biomedicine, 12(4), 285–290.
   Web of Science ®Google Scholar
• Filip, V., et al., 1991. Pharmacokinetics and tolerance of 7-methoxytacrine following the single dose administration in healthy volunteers. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 29(11), 431–436.
   PubMed Web of Science ®Google Scholar
• Fisher, A., et al., 2000. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Annals of the New York Academy of Sciences, 920, 315–320.
   PubMed Web of Science ®Google Scholar
• Freeman, S.E., and Dawson, R., 1991. Tacrine: a pharmacological review. Progress in Neurobiology, 36(4), 257–277.
   PubMed Web of Science ®Google Scholar
• Giacobini, E., 2004. Cholinesterase inhibitors: new role and therapeutic alternatives. Pharmaceutical Research, 50(4), 433–440.
   Web of Science ®Google Scholar
• Grossberg, G.T., 2003. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Current Therapeutic Research, Clinical and Experimental, 64(4), 216–235.
   PubMed Web of Science ®Google Scholar
• Herink, J., Bajgar, J., and Koupilova, N., 1998. Different inhibition of brain acetylcholinesterase activity following intramuscular and intracerebroventricular administration of 7-methoxytacrine. Behavioural Pharmacology, 9, S43.
   Google Scholar
• Hershkowitz, N., and Rogawski, M.A., 1991. Tetrahydroaminoacridine block of N-methyl-D-aspartate-activated cation channels in cultured hippocampal neurons. Molecular Pharmacology, 39(5), 592–598.
   PubMed Web of Science ®Google Scholar
• Horak, M., et al., 2014. ER to synapse trafficking of NMDA receptors. Frontiers in Cellular Neuroscience, 8, 394.
   PubMed Web of Science ®Google Scholar
• Karasova, J.Z., et al., 2011. Partition of bispyridinium oximes (trimedoxime and K074) administered in therapeutic doses into different parts of the rat brain. Journal of Pharmaceutical and Biomedical Analysis, 54(5), 1082–1087.
   PubMed Web of Science ®Google Scholar
• Karasova, J.Z., et al., 2013. Time-dependent changes of oxime K027 concentrations in different parts of rat central nervous system. Neurotoxicity Research, 23(1), 63–68.
   PubMed Web of Science ®Google Scholar
• Karasova, J.Z., et al., 2018a. 1-Benzyl-4-methylpiperidinyl moiety in donepezil: the priority ticket across the blood-brain-barrier in rats. Journal of Chromatography B, 1092, 350–358.
   PubMed Web of Science ®Google Scholar
• Karasova, J.Z., et al., 2018b. The new acetylcholinesterase inhibitors PC-37 and PC-48 (7-MEOTA-donepezil like compounds): characterization of their metabolites in human liver microsomes; pharmacokinetics and in vivo formation of the major metabolites in rats. Basic and Clinical Pharmacology and Toxicology, 122, 373–382.
   PubMed Web of Science ®Google Scholar
• Korabecny, J., et al., 2010a. Synthesis and in vitro evaluation of n-(bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment. Molecules (Basel, Switzerland), 15(12), 8804–8812.
   PubMed Web of Science ®Google Scholar
• Korabecny, J., et al., 2010b. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorganic and Medicinal Chemistry Letters, 20(20), 6093–6095.
   PubMed Web of Science ®Google Scholar
• Korabecny, J., et al., 2014. 7-MEOTA-donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR studies. European Journal of Medicinal Chemistry, 82, 426–438.
   PubMed Web of Science ®Google Scholar
• Kozurkova, M., et al., 2011. Neuroactive multifunctional tacrine congeners with cholinesterase, anti-amyloid aggregation and neuroprotective properties. Pharmaceuticals, 4(2), 382–418.
   Google Scholar
• Misik, J., and Kassa, J., 2014. A comparison of cholinesterase inhibitors in the treatment of quinuclidinyl benzilate-induced behavioural deficit in rats performing the multiple T-maze. Journal of Applied Biomedicine, 12(4), 211–217.
   Web of Science ®Google Scholar
• Misik, J., et al., 2016. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats: Is there a potential for Alzheimer's disease treatment? Neuroscience Letters, 612, 261–268.
   PubMed Web of Science ®Google Scholar
• Moore, A.L., et al., 2002. Calcium mobilization evoked by hepatocellular swelling is linked to activation of phospholipase Cgamma. The Journal of Biological Chemistry, 277(37), 34030–34035.
   PubMed Web of Science ®Google Scholar
• Mzik, M., et al., 2016. An HPLC–MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: application to a pharmacokinetic study. Journal of Chromatography B, 1020, 85–89.
   PubMed Web of Science ®Google Scholar
• Patocka, J., Jun, D., and Kuca, K., 2008. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Current Drug Metabolism, 9(4), 332–335.
   PubMed Web of Science ®Google Scholar
• Racchi, M., et al., 2004. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmaceutical Research, 50(4), 441–451.
   Web of Science ®Google Scholar
• Rusted, J.M., Newhouse, P.A., and Levin, E.D., 2000. Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behavioural Brain Research, 113(1–2), 121–129.
   PubMed Web of Science ®Google Scholar
• Sepsova, V., et al., 2015. Cholinergic properties of new 7-methoxytacrine-donepezil derivatives. General Physiology and Biophysics, 34(02), 189–200.
   PubMed Web of Science ®Google Scholar
• Soares, J., and Gershon, S., 1995. THA–historical aspects, review of pharmacological properties and therapeutic effects. Dementia and Geriatric Cognitive Disorders, 6(4), 225–234.
   Web of Science ®Google Scholar
• Soukup, O., et al., 2011. The effect of oxime reactivators on muscarinic receptors: functional and binding examinations. Environmental Toxicology and Pharmacology, 31(3), 364–370.
   PubMed Web of Science ®Google Scholar
• Soukup, O., et al., 2013. A resurrection of 7-MEOTA: a comparison with tacrine. Current Alzheimer Research, 10(8), 893–906.
   PubMed Web of Science ®Google Scholar
• Spilovska, K., et al., 2015. Design, synthesis and in vitro testing of 7-methoxytacrine-amantadine analogues: a novel cholinesterase inhibitors for the treatment of Alzheimer's disease. Medicinal Chemistry Research, 24(6), 2645–2655.
   Web of Science ®Google Scholar
• Sugimoto, H., 2008. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chemico-Biological Interactions, 175(1–3), 204–208.
   PubMed Web of Science ®Google Scholar
• Summers, W.K., et al., 1986. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. The New England Journal of Medicine, 315(20), 1241–1245.
   PubMed Web of Science ®Google Scholar
• Szilagyi, M., and Lau, W.M., 1993. Interaction of tacrine at M1 and M2 cholinoceptors in guinea pig brain. Pharmacology, 47(4), 223–229.
   PubMed Web of Science ®Google Scholar
• Valis, M., et al., 2017. Concentration of donepezil in the cerebrospinal fluid of AD patients: evaluation of dosage sufficiency in standard treatment strategy. Neurotoxicity Research, 31(1), 162–168.
   PubMed Web of Science ®Google Scholar
• Wagstaff, A.J., and McTavish, D., 1994. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs and Aging, 4(6), 510–540.
   PubMed Web of Science ®Google Scholar
• Watkins, P.B., et al., 1994. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA, 271(13), 992–998.
   PubMed Web of Science ®Google Scholar
• Zhang, X., et al., 2002. Chronic treatments with tacrine and (-)-nicotine induce different changes of nicotinic and muscarinic acetylcholine receptors in the brain of aged rat. Journal of Neural Transmission, 109(3), 377–392.
   PubMed Web of Science ®Google Scholar